Announcements Trials

Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Lung Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1

Interventions

Carboplatin 99 Pemetrexed 71 pembrolizumab 69 Cisplatin 60 Paclitaxel 54 Docetaxel 45 Gemcitabine 37 Erlotinib Hydrochloride 24 Nivolumab 23 osimertinib 17 Bevacizumab 17 durvalumab 14 Cetuximab 13 130-nm albumin-bound paclitaxel 13 Gefitinib 11 Etoposide 11 Drug Therapy 11 Ipilimumab 9 Injections 9 Albumin-Bound Paclitaxel 9 Vinorelbine 8 Radiotherapy 8 motexafin gadolinium 7 capmatinib 7 atezolizumab 7 epacadostat 6 Taxes 6 Cyclophosphamide 6 vandetanib 5 entinostat 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lung Neoplasms × lazertinib × Clear all

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Yuhan Corporation

Approved for marketing

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡